Back to results
US 2017/0360761 A1Published application
Selective Inhibition of HDAC6 and HDAC8, and Methods of Use Thereof
AssigneeReaction Biology Corporation
InventorsHaiching Ma, Yuren Wang
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of selectively modulating (for example inhibiting) the activity of histone deacetylase 6 and/or 8 (HDAC6 and/or HDAC8), and treating HDAC6 and/or HDAC8 associated diseases, including, for example, cancers, inflammatory disorders, and neurodegenerative disorders.
Claims19
A method of selectively inhibiting a histone deacetylase enzyme (HDAC), comprising:
- contacting the HDAC with a compound of Formula RBC-2008, or a salt or solvate thereof:
A method of treating a disease or disorder associated with an HDAC in a subject, comprising:
- administering to the subject a therapeutically effective amount of a compound of Formula RBC-2008, or a salt or solvate thereof:
A method of immunomodulation for organ transplant, comprising:
- administering to a patient a therapeutically effective amount of a compound of Formula RBC-2008, or a salt or solvate thereof:
Dependencies are inferred from the claim text.